Use pSivida Corporation media headlines together with your assets to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.
SunHerald.com - May 17, 2012
WATERTOWN, Mass. -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the expiration on May 15, 2012 of warrants to purchase 2735337 ...
MarketWatch (press release) - May 9, 2012
WATERTOWN, Mass., May 09, 2012 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (asx:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its third quarter ...
pSivida gets UK nod for behind-the-eye treatment - FierceDrugDelivery
pSivida Corporation nears sales of ILUVIEN? in the U.K. with granting of ...
Proactive Investors Australia - May 7, 2012
pSivida Corporation (ASX: PVA, NASDAQ: PSDV) has been granted marketing authorisation in the UK for its ILUVIEN? product for the treatment of vision impairment associated with chronic diabetic macular edema (DME).
pSivida Corp. Announces United Kingdom Grants ILUVIEN? Marketing Authorization ...
SunHerald.com - May 7, 2012
WATERTOWN, Mass. -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the Medicines and Healthcare products Regulatory Agency of the United ...
PSivida Says UK Grants ILUVIEN Marketing Authorization For Treating Chronic DME - RTT News
Psivida, Alimera eye drug gets UK marketing nod - Reuters UK
pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and ...
SunHerald.com - May 3, 2012
WATERTOWN, Mass. -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the third quarter of fiscal year 2012 ...
RTT News - Apr 30, 2012
(RTTNews) - There's an adage that says "eyes are the windows to the soul". But to medical researchers, eyes are windows to health because some diseases could be detected just by looking at our eyes.
pSivida Corp. Announces ILUVIEN(R) Receives Marketing Authorization in Austria ...
MarketWatch (press release) - Apr 24, 2012
WATERTOWN, Mass., Apr 24, 2012 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (asx:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the Austrian Agency for Health and Food ...
New applications for Durasert, pSivida's ($PSDV) back-of-the-eye drug delivery tech, have helped the company nearly double its share price since January, Proactive Investors reports.
PSivida: Small-Cap Ophthalmology-Based BioTech Positioned For Long-Term Growth - Seeking Alpha
pSivida Corporation regains market attention, shares soar 102% since January - Proactive Investors Australia
I believe the following stocks could be on the upside move, today, Wednesday April 18th, 2012, which could make for a nice short term gain for those who prefer short term swing trading.
Seeking Alpha - Apr 11, 2012
Armed with a favorable decision in February that its ILUVIEN sustained-release implant is approvable in the European Union to treat diabetic macular edema (DME), pSivida (PSDV) expects sales of the device to begin by the end of the year.
pSivida Announces Second Tech Evaluation Agreement with its BioErodible ...
Business Wire (press release) - Mar 14, 2012
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has entered into a technology evaluation ...
Mass High Tech - Mar 13, 2012
By Lori Valigra PSivida Corp. (NasdaqGM:PSDV) of Watertown, which is developing sustained drug delivery treatments for back-of-the-eye diseases, said it is in a technology evaluation agreement with ocular drug development company Neuron Systems Inc. of ...
pSivida Announces Second Tech Evaluation Agreement with its BioErodible ... - SunHerald.com
Citybizlist (press release) - Mar 6, 2012
WATERTOWN, Mass. -- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a developer of sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected Douglas Godshall to its Board of Directors.
Based on latest financial disclosure pSivida Corporation has Total Debt of 0.0. This is 100.0% lower than that of Healthcare sector, and 100.0% lower than that of Drug Delivery industry, The Total Debt for all stocks is 100.0% higher than the company.
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
